The Articles You Read Most in 2025 (And Why I Wrote Them)

As 2025 comes to a close, I’ve been reflecting on the writing that mattered most, both to me and to the people who read it. This year, a few articles clearly stood out, not just in page views and shares, but in the conversations they sparked and the messages I received afterward.

These pieces addressed topics I felt strongly needed clarity, nuance, or a more evidence-based lens, especially where misinformation and oversimplification are common. They represent the kind of work I most enjoy creating: thoughtful, science-grounded, and practical content.

If you missed any of these, this is a great place to start.

Does CGM Tell the Whole Story? A Second Look at Lingo for Metabolic Monitoring

This article takes a second look at Abbott’s direct-to-consumer CGM, Lingo, with a focus on its influence on behavior change. While CGM can provide helpful insights into glucose patterns related to food, activity, and metabolic health, it also has important limitations, including the risk of overinterpreting data, subtle nudging toward low-carbohydrate eating, and limited clinical context.

When used thoughtfully, CGM can support metabolic health, but meaningful and safe behavior change depends on education, individualized interpretation, and guidance from qualified professionals.

Why Context and Clinical Guidance Matter

As CGM use for metabolic health increased in my practice, I began to see unintended consequences, including data-related anxiety, excessive food restriction, glucose “perfectionism,” and emerging disordered eating patterns.

I also noticed gaps in understanding among clinicians outside of diabetes care regarding what CGM data can (and cannot) reliably tell us. This article was written to add nuance to the conversation by balancing potential benefits with limitations and reinforcing the need for education and individualized interpretation.

What’s the Deal with GLP-1 Microdosing?

This article examines the growing trend of GLP-1 microdosing, in which medications such as Ozempic, Wegovy, and Zepbound are used at doses well below FDA-approved regimens. It explores what microdosing means, why patients and clinicians are considering it, and the underlying physiology of GLP-1 therapies.

While some real-world experiences suggest potential benefits in select situations, microdosing remains off-label, lacks formal guidelines and long-term safety data, and carries meaningful risks if misapplied. Therefore, a nuanced and evidence-informed approach that balances curiosity with individualized care should reinforce that less is not inherently better without appropriate context and clinical support.

Putting GLP-1 Microdosing in Context

I wrote this article in response to the growing number of questions I receive in my private practice about GLP-1 microdosing, many of which are driven by social media content on platforms like Instagram and TikTok.

Online influencers often present microdosing as widespread and risk-free, creating confusion about its true prevalence, purpose, and safety. I wanted a clear, evidence-based resource where I could organize my research, address common misconceptions, and redirect patients to something they could read outside our virtual visits.

Retatrutide and the Grey Market: Buyer Beware

This article examines the growing hype around retatrutide, a promising but still experimental triple-agonist therapy, and warns against the rising grey-market sale of unapproved versions online.

While early clinical trial data suggest significant potential benefits for weight loss and metabolic health, retatrutide remains in Phase 3 trials and is not FDA-approved, meaning its safety, dosing, and long-term effects are not yet established. Social media platforms are fueling demand by promoting unregulated products and informal “suppliers,” creating serious risks related to quality control, contamination, incorrect dosing, and lack of medical oversight.

Setting the Record Straight on Retatrutide

I wrote this article out of growing concern that people are using retatrutide despite the fact that it is not yet available on the market and remains in clinical trials. Similar to trends seen with GLP-1 microdosing, social media has created the false impression that this medication is widely accessible, safe, and commonly used, when in reality it is not.

I wanted to challenge the idea that “everyone” is using retatrutide and highlight how quickly misleading marketing can spread online, particularly among individuals seeking solutions for weight and metabolic health.

Elevate Your Diabetes Care in 2026

Are you looking to elevate and expand your diabetes care and education services in 2026? Learn how Sarah Hormachea: Diabetes Care and Education, LLC can help strengthen diabetes care delivery. Together, let’s support your team in building scalable, patient-centered solutions that improve care delivery and clinical outcomes.